Navigation Links
Novo Nordisk Submits First Recombinant Treatment for Factor XIII Deficiency for U.S. Regulatory Approval

PRINCETON, N.J., Feb. 23, 2011 /PRNewswire/ -- Novo Nordisk announced today that a Biologic License Application (BLA) has been submitted to the U.S. Food and Drug Administration (FDA) requesting the approval of a recombinant factor XIII compound (rFXIII) for the vast majority of patients with congenital factor XIII (FXIII) deficiency, an inherited bleeding disorder(1). The company anticipates filing its marketing authorization application to the European Medicines Agency in Q2 2011.

Currently, FXIII deficient patients are treated with products derived from human blood plasma(2), which carry an inherent risk of contamination. Treatments created using recombinant technology are genetically engineered and not sourced from human blood or plasma. The use of this technology in the development of treatments helps to reduce the potential risk of transmitting blood-borne illnesses.

Patients with congenital FXIII deficiency have a lifelong susceptibility towards bleeding problems, including spontaneous intracranial hemorrhage. Caused by a lack of the protein clotting factor XIII, FXIII congenital deficiency has a prevalence of one case per two million people(2). With an estimated 600 diagnosed patients worldwide, FXIII deficiency is considered one of the rarest bleeding disorders(3).

"Novo Nordisk is committed to serving the bleeding disorder community, and this submission marks a major milestone in the expansion of our product offerings to this patient group," said Eddie Williams, Vice President of Biopharmaceuticals at Novo Nordisk. "The development of a treatment that does not depend on blood products is an important step for the hundreds of patients affected worldwide by congenital FXIII deficiency."

Positive results from a phase 3 trial examining the efficacy and safety of rFXIII for the prevention of bleeds associated with congenital FXIII deficiency showed that when compared to a historic control group of individuals who did not receive routine FXIII infusions, preventive treatment with monthly recombinant FXIII injections significantly decreased the number of bleeding episodes requiring treatment. These data were presented at the American Society of Hematology (ASH) meeting in December 2010, and marked the first completed phase 3 study conducted to study the use of a recombinant FXIII treatment to prevent bleeding episodes in congenital FXIII deficiency patients.

In the trial, 41 patients were observed over one year, with rFXIII administered as a preventive, once-monthly replacement therapy for FXIII congenital deficiency. Over the course of the treatment period, a total of five bleeding episodes, all associated with trauma and requiring additional FXIII treatment, were observed in four patients. Additionally, no thromboembolic events or fatal adverse events were reported.

About Novo Nordisk Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 30,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchange in Copenhagen. Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Media:

Investors:Outside North America:

Outside North America:Rachel Curtis Gravesen

Klaus Bulow DavidsenTel: (+45) 4442 7603

Tel: (+45) 4442

klda@novonordisk.comIn North America:

Kasper Roseeuw Poulsen Sarah Spielvogel

Tel: (+45) 4442 4471Tel: (+1) 609 240 5333

krop@novonordisk.comsspv@novonordisk.comJannick LindegaardTel: (+45) 4442 4765jlis@novonordisk.comIn North America:Hans RommerTel: (+1) 609 919  Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593–628.

(2)  Karimi M et al.  Factor XIII deficiency. Semin Thromb Haemost 2009;35(4): 426-38.

(3)  National Hemophilia Foundation.  Factor XIII.  Accessed February 8, 2011.

SOURCE Novo Nordisk
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novo Nordisk Creates First Mobile Application to Help Doctors Diagnose Bleeding Disorders
2. Novo Nordisk Intends to Appeal Adverse Ruling in Prandin® (repaglinide) Patent Case
3. Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile
4. Novo Nordisk A/S and Emisphere Technologies, Inc. Announce License Agreement to Develop Oral Formulation of Insulin for Diabetes
5. Novo Nordisk and Chip Ganassi Racing Team Up for 2011 IZOD IndyCar Series
6. Novo Nordisk and Entertainment Industries Council Work Together to Improve Public Education and Awareness about Diabetes Epidemic
7. Novo Nordisk to Invest $73m in Expansion of U.S. Manufacturing Facility
8. Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg
9. Novo Nordisk Addresses Innovation in Diabetes Care in Second Issue of Industry Resource for Information on Diabetes and Chronic Disease
10. Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp
11. Novo Nordisk Awards More Than $300,000 in Grants to Support Education and Community Health Programs
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):